Instead of combining KRASG12C inhibitors with ICB, another attractive direction is developing bispecific T cell engagers targeting KRAS mutant peptide-MHC I complex on the surface of KRASG12C mutant cancer cells.501,502 Currently, these bispecific T cell engagers based on a KRASG12C inhibitor conjugated neoepitopes have been reported to cause cytotoxic T cells response in a co-culture system with T cells in vitro. The gene discussed is KRAS; the disease is cancer.